The company reported mixed fourth-quarter results, missing earnings per share estimates but beating sales expectations. Executives acknowledged a challenging consumer health market and ongoing difficulties in its infant formula business. The primary negative driver was the issuance of 2026 sales and profit guidance that fell below market expectations, citing persistent headwinds in infant formula. This weak forward outlook caused the company's stock price to decline following the earnings announcement.